Compare HMY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | PRAX |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.3B |
| IPO Year | 2002 | 2020 |
| Metric | HMY | PRAX |
|---|---|---|
| Price | $16.90 | $260.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 19 |
| Target Price | $22.19 | ★ $644.42 |
| AVG Volume (30 Days) | ★ 2.9M | 441.7K |
| Earning Date | 02-04-2016 | 11-04-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $13.94 | $39,458.00 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.03 | $50.56 |
| 52 Week High | $26.04 | $392.70 |
| Indicator | HMY | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 27.51 |
| Support Level | $15.29 | $238.77 |
| Resistance Level | $18.30 | $337.47 |
| Average True Range (ATR) | 0.45 | 13.90 |
| MACD | -0.19 | -1.34 |
| Stochastic Oscillator | 20.08 | 2.21 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.